Background Cervical cancer screening might contribute to the prevention of anal cancer in women. We aimed to investigate if routine cervical cancer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathology-predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL) and, hence, anal cancer.
Introduction
Compared with knowledge of how cervical high-risk human papillomavirus (HPV) infection and cervical cytohistopathological results are related to cervical cancer, less is known about how cervical screening results might predict anal cancer. A better understanding would help to prioritise women at greatest risk of anal cancer for secondary prevention measures in new HPV-based cervical cancer screening programmes.
Annually, about 18 000 women are diagnosed with anal cancer worldwide 1 and, although rare at a population level, anal cancer is more frequent in women than in men. 2 Furthermore, anal cancer incidence rates are increasing, 2 probably owing to changes in sexual risk factors for HPV transmission. 3 Persistent anal HPV infection is the major cause of anal cancer, 4 for which the most severe precursor is anal high-grade squamous intraepithelial lesion (HSIL). 5 In particular, HPV16 is detectable in over 90% of HPV-related anal cancers and 80% of HPV-related anal HSIL 5 , a substantially higher attributable fraction than in the cervix. Anal cancer risk is also elevated in women infected with HIV, [6] [7] [8] although HIV does not account for a substantial proportion of anal cancer in women at a population level. 9, 10 Women with a history of cervical cancer 9, 11, 12 and cervical intraepithelial neoplasia grade 3 (CIN3) [13] [14] [15] are also at increased risk for anal cancer.
To assess the association between cervical screening findings and surrogates of anal cancer risk, we did a collaborative pooled analysis of high-risk HPV and related lesions in paired anal and cervical samples. We hypothesised that it would be possible, based on HIV status and cervical screening results, to robustly identify subgroups of women with high prevalence of anal HPV16, anal HSIL, or HPV16-positive anal HSIL for the purpose of targeting anal cancer screening and early diagnosis.
Methods

Data collection
We previously did a systematic literature review for a metaanalysis of anal HPV prevalence according to anal cytohistopathology, sex, and HIV status. We searched MEDLINE, Embase, and the Cochrane Library for studies published between Jan 1, 1986, and July 31, 2017, using the terms ("papillomaviridae" OR "papillomavirus" OR "HPV") AND ("anal canal" OR "anus" OR "anal"). 5 The same search strategy was extended to Aug 31, 2018 and identified 49 studies eligible for a pooled analysis of cervical determinants of anal HPV and HSIL (appendix p 2). Minimum eligibility criteria were paired anal and cervical samples (swabs or biopsies, or both) taken at the same study visit; in anal samples, type-specific HPV DNA detected by a PCR-based assay; and, in cervical samples, type-specific HPV DNA detected by a PCR-based assay, cytohistopathology results, or both. Authors of eligible studies were invited to share individual-level data on age, anal and cervical HPV genotyping, cervical cytohistopathology, and HIV status (including unknown HIV status), of which 36 accepted (appendix p 2). Anal cytohistopathology results from the same study visit were also extracted, if available, as were current and nadir CD4 cell count and HIV-1 viral load for HIV-positive women.
Statistical analysis
Type-specific HPV prevalence in the anus and cervix is reported for 13 high-risk HPV types judged to be carcinogenic or probably carcinogenic (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 68), 4 and is estimated only in studies that tested for the given high-risk HPV type, thus denominators vary by type, as in previous similar meta-analyses. 5, 16 Anal HPV16 prevalence was available in all studies.
Anal and cervical cytohistopathological diagnoses were classified into four categories, as done previously: 5, 16 normal, including normal cytology only; low grade, including atypical squamous cells of undetermined significance, lowgrade squamous intraepithelial lesion, and intraepithelial neoplasia grade 1; high grade, including HSIL, atypical squamous cells for which HSIL cannot be excluded, intraepithelial neoplasia grade 2-3; and invasive cancer. We
Research in context
Evidence before this study We searched MEDLINE, Embase, and the Cochrane Library for studies published between database inception and Aug 31, 2018, using the search terms ("papillomaviridae" OR "papillomavirus" OR "HPV") AND ("anal" OR "anus" OR "anal canal"), without language restrictions. A large systematic review and meta-analysis has shown the predominant role of HPV16 in the pathogenesis of anal high grade squamous intraepithelial lesion (HSIL) and cancer, both in men and women, and according to HIV status. Various studies, predominantly from high-income settings, have also shown that anal cancer incidence is higher in women than in men, is increasing over time and, among women, is particularly elevated in those with cervical precancer or cancer, or living with HIV. However, there has been no systematic appraisal of how routinely available information from cervical cancer screening-ie, cervical HPV infection and cytohistopathology-is predictive of risk of anal cancer or its surrogates.
Added value of this study
This collaborative pooled analysis is the first systematic effort to address how routinely available information from modern cervical cancer screening programmes-cervical HPV and cytohisto pathology results-can predict anal HPV16, anal HSIL, or HPV16-positive anal HSIL, as best surrogates of anal cancer risk in women. We showed that cervical HPV infection, cervical cyto histopathological diagnosis, HIV status, and their combinations, are all associated with anal HPV16, anal HSIL, or HPV16-positive anal HSIL. The strongest determinants of these outcomes were the presence of cervical HPV16 infection or a diagnosis of cervical cancer, irrespective of HIV status. The degree of HIV-related immunodeficiency was also weakly associated.
Implications of all the available evidence
Women with cervical HPV16 infection or cervical cancer are at highest risk of anal HPV16, anal HSIL, or HPV16-positive anal HSIL. HPV-based cervical screening programmes might help to stratify anal cancer risk in women, irrespective of their HIV status.
calculated prevalence ratios (PRs) from generalised linear models, with adjustment for age (<30 years, 30-44 years, and >45 years). Age-adjusted PRs and corresponding 95% CIs were used to compare prevalence of type-specific anal HPV (most notably HPV16), anal high-grade lesions (ie, HSIL), 17 and HPV16-positive anal HSIL, according to cervical high-risk HPV status, cervical cytohistopathology, age (<30 years, 30-44 years, and >45 years), and HIV status (negative or unknown vs positive). Among HIV-positive women, PRs were also calculated according to current CD4 cell count (<350 cells per μL, 350-499 cells per μL, or >500 cells per μL; defined as rough tertiles of available data), nadir CD4 count (<200 cells per μL or >200 cells per μL), and HIV viral load (<200 copies per mL or >200 copies per mL). All statistical analyses were two-sided and done in Stata (version 14).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.
Results
We included 36 studies contributing individual-level data on 13 Cervical high-risk HPV positivity was associated with anal high-risk HPV prevalence (table 2). In HIV-negative women, anal high-risk HPV prevalence was 43% (1160/2693) in cervical high-risk HPV-positive women versus 9% (563/6543) in cervical high-risk HPV-negative women (PR 4·9, 95% CI 4·4-5·3, p<0·0001). In HIV-positive women, these proportions were 62% (678/1091) for HPV-positive women and 33% (579/1770) for HPV-negative women (1·9, 1·7-2·1, p<0·0001). Associations for individual high-risk HPV types were much stronger than for high-risk HPV overall (table 2) . For example, for HIV-negative women, anal HPV16 prevalence was 41% (447/1097) in cervical HPV16-positive versus 2% (214/8663) in cervical HPV16-negative women (16·5, 14·2-19·2, p<0·0001; table 2). Equivalent proportions were 46% (125/273) and 11% (272/2588) in HIVpositive women (4·4, 3·7-5·3, p<0·0001).
For each high-risk HPV type, the association between cervical and anal positivity was weaker among HIVpositive than HIV-negative women (table 2). In cervical HPV16-negative women, anal HPV16 prevalence was 11% in HIV-positive women versus 2% in HIV-negative women (PR 3·9, 95% CI 3·3-4·7, p<0·0001); whereas, in HPV16-positive women, anal HPV16 prevalence was 46% in HIV-positive women versus 41% in HIV-negative women (1·1, 1·0-1·3, p=0·1501). Anal HPV16 prevalence was higher in cervical high-risk HPV-positive women than in cervical high-risk HPV-negative, regardless of HIV status (PR 9·2, 95% CI 7·5-11·2, p<0·0001 for HIV-negative women vs 2·4, 2·0-2·9, p<0·0001 for HIVpositive women; figure 1). Anal HPV16 prevalence was highest among cervical HPV16-positive women (table 2), but was also significantly higher in women infected with cervical non-HPV16 high-risk HPV than in women without high-risk HPV (2·1, 1·5-2·8, p<0·0001 for HIVnegative; 1·5, 1·2-1·9, p=0·0003 for HIV-positive women).
Cervical cytohistopathology was strongly associated with anal HPV16, particularly in HIV-negative women, among whom it increased from 4% (155/4358) in women with normal cytology to 22% (251/1131) in those with HSIL (PR 6·5, 95% CI 5·4-7·9, p<0·0001) and to 44% (101/228) in those with cervical cancer (14·1, 11·1-17·9, p<0·0001; figure 1A ). Associations were also significant, albeit lower, in HIV-positive women (13% [230/1821] for normal cytology up to 23% [29/127] for HSIL; 1·9, 1·3-2·6, p=0·0004). Age was not a strong determinant of anal HPV16 prevalence, regardless of HIV status. Cervical cancer cases in HIV-positive women were too few (n=3) to be analysed separately. figure 1B) . However, neither cytohistopathology, nor age, offered much discrimination of anal HPV16 prevalence, neither for HIV-negative nor HIV-positive women. Anal HPV16 prevalence according to other strata of cervical high-risk HPV status (cervical high-risk HPV-negative, cervical high-risk HPV-positive, and cervical non-HPV16 high-risk HPV-positive only) is shown in the appendix (p 4).
HIV status was a determinant of anal HPV16 prevalence within almost all strata of cervical cytohistopathology and age ( figure 1A ), but not in any stratum of cervical HPV16-positive women (figure 1B).
A subset of studies had data on anal cytohistopathology (1003 HIV-negative women from ten studies and 2252 HIV-positive women from 13 studies, table 1). Anal HSIL was associated with cervical high-risk HPV, both in HIV-negative women (from 2% [11/527] Cervical high-risk HPV-positive women had higher anal HSIL prevalence than did cervical high-risk HPVnegative women, regardless of HIV status (PR 10·4, 95% CI 5·5-19·5, p<0·0001 for HIV-negative women; 1·7, 1·3-2·2, p=0·0001 for HIV-positive women; figure 2A ). For cervical HPV16-positive women, PRs versus cervical high-risk HPV-negative women reached 12·9 (95% CI 6·7-24·8, p<0·0001) and 2·3 (1·6-3·4, p<0·0001), for HIV-positive and HIV-negative women, respectively. Anal HSIL was also more common among women with cervical HPV16 than among women with cervical non-16 high-risk HPV, both in HIV-negative women (1·5, 1·0-2·5, p=0·0666) and HIV-positive women (1·6, 1·1-2·3, p=0·0227). Anal HSIL was associated with cervical cytohistopathology, particularly with cervical HSIL (PR vs normal cytology 23·1, 9·4-57·0, p<0·0001 in HIV-negative women, 3·6, 2·5-5·3, p<0·0001 in HIV-positive women) and cervical cancer (15·0, 4·3-52·3, p<0·0001 in HIV-negative women; figure 2A ). Anal HSIL prevalence increased with age, but was significantly different only in HIV-positive women (2·5, 1·6-4·1, p=0·0001; figure 2A) .
Among cervical HPV16-positive women, anal HSIL prevalence increased with advancing age (figure 2B). In HIV-negative women, HSIL prevalence was 38% (8/21) in those older than 45 years versus 17% (9/52) in those younger than 30 years (PR 2·2, 95% CI 1·0-4·9, p=0·0552); these values were 26% (14/53) versus 5% (3/58) in HIV-positive women (5·1, 1·6-16·8, p=0·0072; figure 2B ). Anal HSIL prevalence is shown for other strata of cervical high-risk HPV status in the appendix (p 5).
HIV status was a significant determinant of anal HSIL for women in lower risk strata-for example, cervical high-risk HPV-negative women (PR 3·5, 95% CI 1·9-6·5, p=0·0001; figure 2A ) and women with normal cervical cytology (PR 6·9, 2·8-16·9, p<0·0001; figure 2A )-but was not a significant determinant in any stratum of cervical HPV16-positive women ( figure 2B ). Prevalence of HPV16-positive anal HSIL was substantially higher in cervical high-risk HPV-positive women than in high-risk HPV-negative women (PR 14·8, 95% CI 3·3-66·3, p=0·0004 for HIV-negative and 3·0, 1·8-4·8, p<0·0001 for HIV-positive women; figure 3A ), largely due to the strong association with cervical HPV16-positivity (24·9, 5·5-112·7, p<0·0001 for HIV-negative women and 6·2, 3·6-10·6 p<0·0001 for HIV-positive women; figure 3A ). There were also significant associations with cervical cytohistopathology, most clearly with cervical HSIL versus normal cytology (PR not defined, 95% CI 2·6-∞ in HIV-negative women and PR 4·3, 2·4-7·8, p<0·0001 in HIV-positive women), but not with age ( figure 3A) .
In cervical HPV16-positive women, there was a strong association between HPV16-positive anal HSIL and age (figure 3B). In HIV-negative women, HPV16-positive anal HSIL prevalence was 25% (5/20) in women older than 45 years versus 4% (2/46) in women younger than 30 years (PR 5·8, 1·2-27·2, p=0·0273); in HIVpositive women, these values were 23% (12/52) versus 2% (1/55; 12·7, 1·7-94·2, p=0·0130). HPV16-positive anal HSIL prevalence is shown for other strata of cervical high-risk HPV status in the appendix (p 6). HIV status was a significant determinant of HPV16-positive anal HSIL in cervical high-risk HPV-negative women (PR 5·2, 95% CI 1·2-22·1, p=0·0242; figure 3A), women with normal cervical cytology (PR not defined, 2·1-∞, p<0·0001), and with cervical HSIL (2·7, 1·2-5·9, p=0·0142), but not in any stratum of cervical HPV16-positive women ( figure 3B) .
In HIV-positive women (appendix p 7), current CD4 cell count was significantly, albeit weakly, associated with anal HPV16 (for <350 cells per μL vs >500 cells per μL; PR 1·6, 95% CI 1·3-1·9, p<0·0001), anal HSIL (1·7, 1·3-2·2, p=0·0003), and HPV16-positive anal HSIL (1·6, 1·0-2·6, p=0·0365) . Similar findings were seen for nadir CD4 cell count (appendix p 7). HIV viral load was positively associated with anal HPV16, but not with anal HSIL or HPV16-positive anal HSIL (appendix p 7).
Among HIV-positive women with cervical HPV16 infection (appendix p 7), anal HPV16 prevalence was highest in cervical HPV16-positive women with a current CD4 cell count of less than 350 cells per μL. No associations were seen for cervical HPV16-positive women in terms of HIV-related immunosuppression and anal HSIL nor HPV16-positive anal HSIL (appendix p 7).
Discussion
This collaborative pooled analysis is, to our knowledge, the first systematic effort to address how routine information from modern cervical cancer screening programmes HIV infection and severity of immunodeficiency are also strong determinants, but they offer little additional risk discrimination over status of cervical HPV genotype and cytohistopathology. Findings were broadly similar whether using anal HPV16 infection or anal HSIL as an outcome, and were consistent when restricted to a combined outcome of HPV16-positive anal HSIL, which highlighted age as a strong determinant of risk in cervical HPV16-positive women.
A strong association between the presence of high-risk HPV in cervical and anal specimens was confirmed. 46, 51 However, the pooled analysis showed an even stronger association at the HPV type-specific level, suggesting shared exposure routes, with the cervix serving as a reservoir for HPV cross-infection of the anus or vice versa. 54 Given that studies in women have reported associations between anal sexual intercourse and anal HPV to be either non-significant, 47 or less important than number of sexual partners per se, 46, 51 it is likely that HPV exposure is predominantly from cervix to anus. This exposure could be assisted by a sexual partner or, given the close anatomical proximity, non-sexual autoinoculation. These findings highlight notable differences from anal HPV transmission in men. 55 Given the unique anal carcinogenicity of HPV16, 5 our primary objective was to measure female determinants of anal HPV16 prevalence as a surrogate of anal cancer risk. The prevalence of anal HPV16 is about 30% in HIV-positive men who have sex with men (MSM), 55 a population widely considered to be at a clinically relevant elevated risk of anal cancer, and the focus of numerous anal cancer prevention recommendations. [56] [57] [58] Using this benchmark, female subpopulations with clinically relevant elevated anal HPV16 prevalence included women with cervical cancer (44%), corroborating the excess anal cancer risk found in cancer registry-based studies, [11] [12] [13] followed by those with cervical HPV16 infection (39% in HIV-negative women, 46% in HIV-positive women), for which no studies of anal cancer outcomes exist.
In the absence of cervical genotyping for HPV16 or a history of cervical cancer, some discrimination of anal HPV16 prevalence can also be offered by cervical high-risk HPV, cervical cytopathology, and HIV status. For example, anal HPV16 prevalence is relatively high in HIV-positive women with cervical high-risk HPV infection (22%) or cervical HSIL (23%). In general, HIV-positive women had higher anal HPV16 prevalence than did HIV-negative women, supporting their known excess risk of anal cancer.
6-8 Severity of immunosuppression, although a risk factor for anal cancer, 8, 59 was a relatively weak determinant of anal HPV16 prevalence (and anal HSIL) in HIV-positive women, which is consistent with findings in HIV-positive MSM. 60, 61 Given that the non-HPV16 high-risk HPV fraction of anal cancer is somewhat larger in HIV-positive than in HIV-negative women, 5 anal HPV16 prevalence is arguably a less-specific surrogate of anal cancer risk in HIV-positive women. However, no other non-HPV16 high-risk HPV type clearly stands out as being associated with an increased risk of anal cancer; 5 not even HPV18, which does for cervical cancer. Therefore, we postulate that anal HPV16 still remains the most-specific virological surrogate of anal cancer risk, even in HIV-positive women.
As a complement to anal HPV16 as a surrogate for anal cancer risk, we also evaluated anal HSIL. Whereas anal HPV16 prevalence was standardly reported and measured by PCR-based assay in all studies, anal cytohistopathology was available only for about 24% of the study population. Furthermore, anal HSIL represents lesions reported according to cytology or histology (or both), the results of which were inextricably entwined (especially given the move towards harmonisation of cytology or histology nomenclature), 17 and might also be influenced by differing expertise in high-resolution anoscopy to detect biopsydirected histological HSIL. 62 Despite these caveats, patterns of anal HSIL were broadly similar to those found for anal HPV16, with positivity for cervical HPV16 infection (24% prevalence of anal HSIL in HIV-negative women) or history of cervical cancer (17% prevalence of anal HSIL) being strong determinants of anal HSIL risk. These values compare to 24% prevalence of histological HSIL estimated in a large meta-analysis of HIV-positive MSM. 63 22 (36%) of the 61 HIV-negative women with anal HSIL and 11 (5%) of the 217 HIV-positive women with anal HSIL were anal HPV-negative. HPV16 accounted for 41% (for HIV-negative women) and 42% (for HIVpositive women) of HPV-positive anal HSIL, which compares to 56% (for HIV-negative women) and 36% (for HIV-positive women), estimated in a wider meta-analysis of anal HSIL. 5 However, the meta-analysis showed further enrichment in HPV16 from anal HSIL to anal cancer, 5 irrespective of HIV status, suggesting that HPV16-positive anal HSIL is the most specific anal cancer surrogate. Although this outcome suffers from the same limitations of ascertainment as anal HSIL does, HPV16-positive anal HSIL showed strongest risk discrimination (ie, highest PRs) by cervical determinants, most notably by cervical HPV16 infection, cervical HSIL, and age group. Older age offered significant additional discrimination of HPV16-positive anal HSIL risk in cervical HPV16-positive women.
With respect to population representativeness, we did not present outcomes for HIV-negative women overall, given that many studies biased recruitment towards HIV-negative women with cervical lesions. For example, whereas anal HPV16 prevalence in HIV-negative women was 7% overall, it was only 3% in four large populationbased studies totalling 6508 women. 21, 29, 46, 51 Strata by cervical HPV and cytohistopathology, however, are expected to be representative of these subpopulations of HIV-negative women. HIV-positive women are also likely to be representative, because studies tended to recruit all patients in HIV clinics in a given time frame, without other selection criteria.
Our study has some limitations. First, the small numbers in certain important strata, most notably cervical HPV16-positive women with respect to the outcome of HPV16-positive anal HSIL. Second, the included studies lacked data on anal outcomes related to three areas: in HIV-positive women with cervical cancer, presumably due to their relative rarity at a population level (although we assume that they would show an anal cancer risk profile at least as bad as HIVnegative women with cervical cancer); according to the use of combined antiretroviral therapy (we addressed the issue of immune reconstitution through CD4 cell counts and HIV viral load); and by HPV vaccination status, although study years, country, and the age group of women suggest that most women were ineligible for HPV vaccination.
The rarity of anal cancer at a population level, combined with a scarcity of medical expertise and capacity-whether in digital anal rectal examination for early cancer diagnosis, or anal cytology in combination with high-resolution anoscopy for the detection and treatment of dysplastic anal lesions-means that any secondary anal cancer prevention programme needs to target the groups at highest risk. Although the effectiveness of such programmes is still to be established, 64 when such activities do exist, they should at least prioritise individuals according to an approach of equal management for equal risk. To date, secondary prevention in women has focused on HIV-positive populations and certain guidelines for HIV management make specific recommendations. [56] [57] [58] For example, the European AIDS Clinical Society advises digital rectal examination (with or without anal cytology) every 1-3 years for women with cervical dysplasia; 56 similarly, France recommends digital rectal examination and anoscopy for women with cervical dysplasia, with the option of expanding this approach to all HIV-positive women if local capacity allows. 57 New York State (USA) recommends digital rectal examination for all HIV-positive women, and annual cytology for those with cervical HSIL. 58 Thus, when recommendations for HIV-positive women exist, they tend to focus on women with cervical lesions and tend also to mirror those for HIV-positive MSM in the same setting. [56] [57] [58] The elevated anal cancer risk profile for HIV-positive women with cervical HSIL in the present work supports prioritisation over other HIV-positive women for secondary anal cancer prevention. However, in an era of shifting towards HPV-based cervical screening, the finding that HIV-positive women with cervical HPV16 infection (about 10% of HIV-positive women in this pooled analysis) have an at least similar anal cancer risk profile suggests they deserve similar prioritisation.
Expanding secondary anal cancer prevention beyond HIV-positive women would pose substantial problems of upscaling and require appropriate weighting of benefit versus risk. Nevertheless, HIV-negative women with cervical HPV16 had an anal cancer risk profile similar to that of HIV-positive women (and HIV-positive MSM) and arguably deserve equivalent anal cancer prevention management. Indeed, in high-income settings, the population burden of female anal cancer is largely unaffected by HIV 9,10 and so requires intervention in the HIV-negative population. As HPV-based cervical screening becomes more widespread, our findings advocate for further research into anal disease burden and prevention among HIV-negative cervical HPV16-positive women. There should be a particular focus on older generations of women who have missed out on the opportunity of prevention through HPV vaccination and in whom cervical HPV16 infection is rarer and more likely to represent long-standing persistent infection. Although numbers were small, half of all cervical HPV16-positive women aged older than 45 years harboured anal HPV16, and one quarter had HPV16-positive anal HSIL. Population-based anal cancer incidence begins to rise only in the fifth decade of life, 10 10 years later than that for cervical cancer, so secondary prevention might also begin about 10 years later.
In summary, the prevalence of anal HPV16 infection, anal HSIL, or HPV16-positive HSIL can be used as surrogates to classify female subpopulations with different anal cancer risk. Such an approach is validated by identification of established high-risk groups-namely, women diagnosed with cervical precancer or cancer, or living with HIV. With respect to identifying the highest risk populations for targeted secondary prevention, HIV-negative women with cervical HPV16 infection, particularly those older than 45 years, had an anal cancer risk profile, based on these surrogate measures, that was similar to that of HIV-positive women.
